Gaylord Specialty Healthcare
Pete Grevelding was appointed Vice President, Clinical Operations in October 2018. He is responsible for the oversight of Gaylord Specialty Heathcare’s clinical areas, including leadership of the Admissions, Inpatient and Outpatient Therapy, Respiratory, and Care Management departments. His responsibilities include facilitating hospitalwide growth and volume targets as well as driving key business initiatives that enhance Gaylord Specialty Healthcare’s market share and profitability. Grevelding has a lead role in maximizing patient satisfaction and recovery by evaluating, coordinating, and implementing institutional programs, policies and strategy. He is responsible for implementing strategies that promote Gaylord’s core values and culture to maximize performance and service while increasing overall achievements.
Grevelding has spearheaded the growth of Gaylord’s existing research program as an opportunity to share Gaylord’s experience and expertise. He has championed several partnerships and currently oversees corporate research partnerships between Gaylord and ZeroG, a robotic bodyweight support system that enables dynamic gait and balance training, and Connecticut-based Hyperfine, the manufacturer of portable, low-dose radiation MRI. In 2020, Grevelding was named Executive Director of the Milne Institute for Healthcare Innovation.
A graduate of the University of Connecticut with a Master’s of Science degree in Physical Therapy, Grevelding is a board certified Neurologic Clinical Specialist and a member of the American Physical Therapy Association and Neurologic Section of the APTA. His career with Gaylord began in March 2004 as a staff physical therapist. He has since held various positions of leadership at Gaylord such as the Director of Therapy Services & Business Development and the Manager of Therapy Services. Pete also has experience working in rehabilitation hospitals and outpatient settings. His professional interests include traumatic brain injury, stroke, research, and progressive clinical growth.